Under 25? Talk to a licensed clinician and get baseline labs before starting anything. Why we say this · Labs checklist
# Survodutide Dosing Guide: Phase 2–3 Weekly Doses for Obesity
> Note: PeptIQ is not a medical provider. Survodutide is an investigational dual agonist. Doses below reflect published trial designs — not a consumer protocol.
Survodutide (BI 456906) is a once-weekly glucagon receptor / GLP-1 receptor dual agonist. If retatrutide made people search "triple agonist dosing," survodutide is the dual-agonist cousin with a growing Phase 3 footprint — including SYNCHRONIZE obesity readouts.
Quick Answer: Survodutide Dosage
Program
Weekly SC doses studied
Phase 2 dose-finding (46 weeks)
0.6, 2.4, 3.6, 4.8 mg (plus placebo)
Phase 3 SYNCHRONIZE-1 (76 weeks)
Dose adjusted up to 3.6 mg or 6.0 mg vs placebo
Route: subcutaneous, once weekly, with a formal dose-escalation period before maintenance.
Phase 2: What the Dose-Finding Trial Showed
In the Lancet Diabetes & Endocrinology Phase 2 obesity trial (no diabetes), participants escalated over ~20 weeks then maintained through week 46.
Approximate mean weight change at week 46 (planned treatment analysis):
Weekly dose
Approx. mean weight change
0.6 mg
~−6%
2.4 mg
~−12.5%
3.6 mg
~−13%
4.8 mg
~−15%
Placebo
~−3%
GI adverse events were common — the same class pattern as other incretin / glucagon dual agonists. Escalation length matters.
Phase 3: SYNCHRONIZE-1 Dosing Context
SYNCHRONIZE-1 randomized adults with obesity (or overweight + comorbidity, excluding diabetes) to weekly survodutide adjusted up to 3.6 mg or 6.0 mg, or placebo, for 76 weeks.
Public treatment-regimen estimand results at week 76:
Arm
Mean weight change
Up to 3.6 mg
~−12.2%
Up to 6.0 mg
~−13.0%
Placebo
~−5.4%
Efficacy estimands (modeling full adherence) were higher (mid-teens % range in public summaries). Liver-fat and visceral-fat substudy signals are part of why glucagon activity is interesting beyond the scale.
Titration Logic (Educational)
Dual agonists with glucagon activity are not "start at the top dose" drugs.
Typical trial pattern:
Start low
Step up on a fixed schedule (often over many weeks)
Only hold/reduce for tolerability per protocol
Spend the majority of the trial at maintenance
If you are comparing to retatrutide community titration charts, remember: survodutide milligrams are not retatrutide milligrams.
Survodutide vs Retatrutide vs Tirzepatide (Dosing Mental Model)
Drug
Receptor story
Dosing vibe
Tirzepatide
GLP-1 + GIP
Approved weekly titration ladders
Survodutide
GLP-1 + glucagon
Investigational weekly dual agonist
Retatrutide
GLP-1 + GIP + glucagon
Investigational weekly triple agonist
Glucagon is why people talk about energy expenditure and liver fat — and why GI titration discipline still matters.
What to Track
Weekly dose step and date
Nausea / vomiting / constipation scores
Protein intake and lifting
Average weight + waist
Optional: liver enzymes / imaging if clinically ordered (MASLD interest)
FAQ
Q: What is the usual survodutide dose?
A: There is no approved consumer dose. Phase 3 obesity arms targeted maintenance up to 3.6 mg or 6.0 mg weekly after escalation.
Q: Is survodutide daily?
A: No — once weekly in the obesity programs described here.
Q: Is 6 mg better than 3.6 mg?
A: In SYNCHRONIZE-1 public averages, 6.0 mg was modestly higher on mean weight loss under the treatment-regimen estimand; tolerability and individual response still dominate decisions in any future labeled use.
Q: Can I run survodutide with retatrutide?
A: Do not stack investigational multi-agonists casually. Overlapping pathways raise safety and attribution problems.
Bottom Line
Survodutide dosing in public science lands on weekly SC escalation toward the mid-single-digit milligram range, with Phase 2 exploring up to 4.8 mg and Phase 3 focusing on 3.6 mg and 6.0 mg maintenance targets. Treat those numbers as trial literacy for a hot dual agonist — not a DIY chart.
Download PeptIQ to log weekly dual-agonist style protocols cleanly.
